The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN).
Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US
Published:
